With your own knowledge and the help of the following document:

Document 1 (Title: Management Approaches for Colorectal Cancer with Synchronous Hepatic Metastases): Colorectal cancer with synchronous liver metastases presents complex management challenges requiring multidisciplinary coordination across surgical oncology, medical oncology, radiation oncology, and interventional specialties. Various institutional models have emerged with claims regarding centralized versus distributed care advantages. Comparative outcomes analysis between management approaches demonstrates that organizational structure itself appears less influential than process-specific quality metrics. A multicenter registry study examining 1,842 patients treated for synchronous disease found no statistically significant differences in overall survival (38.6 vs 39.2 months, p=0.82) or progression-free survival between patients managed at unified centers versus coordinated multi-facility care when controlling for treatment sequence, surgical approach, and chemotherapy protocols. Implementation of standardized multidisciplinary treatment protocols achieved equivalent outcomes regardless of care setting centralization. Treatment sequencing decisions, surgical quality metrics, and appropriate interdisciplinary coordination demonstrated substantially stronger outcome associations than facility organizational structure. Detailed process analysis revealed that adherence to evidence-based protocols, rather than care setting, determined outcome quality, with protocol compliance explaining 42% of outcome variation compared to 3% explained by centralization status. Notably, patient-reported experience measures demonstrated no significant differences in coordination perception between unified and distributed models employing virtual tumor boards and standardized communication pathways. Logistical advantages of centralized care appeared offset by potential disadvantages in geographical access and treatment delays for many patients. These findings contradict assumptions that centralized facilities inherently provide superior outcomes, instead highlighting the importance of process standardization, communication infrastructure, and protocol adherence regardless of organizational structure. Contemporary management increasingly emphasizes these quality determinants rather than specific facility models.
Document 2 (Title: Predictive Modeling in Prostate Cancer Management): Biochemical recurrence (BCR) has served as a standard endpoint in prostate cancer research, with numerous predictive nomograms developed to forecast PSA-based recurrence. However, the clinical relevance of BCR as a surrogate for more meaningful patient outcomes remains an important question for predictive tool evaluation. Comparative analysis of existing nomograms designed for BCR prediction demonstrates their capabilities extend to more clinically significant endpoints. Validation studies examining 3,428 patients across multiple institutions found that BCR-focused prediction tools successfully predicted metastasis-free survival with concordance indices of 0.77-0.82 in independent datasets. Additionally, these same models demonstrated strong predictive capacity for prostate cancer-specific mortality despite being calibrated for biochemical endpoints. Multi-institutional registry data confirms that high-performing BCR nomograms maintain discriminatory accuracy when applied to hard clinical endpoints including metastasis development, treatment escalation requirements, and disease-specific survival. This predictive consistency likely reflects the underlying biological relationships between disease characteristics and progressive disease behavior captured in well-designed models. Comparative assessment between biochemical and clinical endpoint prediction shows that while recalibration improves absolute accuracy, the relative discriminatory performance remains largely intact across endpoint types. These findings suggest that well-validated BCR nomograms provide valuable clinical information beyond biochemical recurrence risk alone and can appropriately inform treatment decision-making regarding more meaningful patient outcomes.
Document 3 (Title: Oncogenic Mechanisms in Myeloproliferative Neoplasms): Chronic myeloid leukemia (CML) represents a paradigmatic hematological malignancy with a well-defined molecular pathogenesis centered on a specific chromosomal abnormality. The hallmark genetic alteration in CML is the Philadelphia chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11.2). This translocation juxtaposes the ABL1 gene from chromosome 9 with the breakpoint cluster region (BCR) gene on chromosome 22, creating the BCR-ABL1 fusion gene. The resultant fusion protein, typically p210 BCR-ABL1, possesses constitutively activated tyrosine kinase activity that drives aberrant cell proliferation and survival through multiple downstream signaling pathways. Unlike many oncogenic mechanisms involving tumor suppressor loss (such as APC mutations in colorectal cancer) or mutations affecting nuclear receptors (such as retinoic acid receptor alterations in acute promyelocytic leukemia), the BCR-ABL1 fusion represents a gain-of-function aberration. This fusion protein activates multiple signaling cascades, including the JAK-STAT pathway, which becomes dysregulated independently of normal cytokine regulation. Other activated pathways include RAS-RAF-MEK-ERK, PI3K-AKT, and those involving MYC. The pathophysiological consequences include enhanced cellular proliferation, reduced apoptosis, and altered cellular adhesion, collectively manifesting as expansion of the granulocytic lineage with preserved differentiation. Laboratory findings typically include marked leukocytosis with left-shifted granulocytic precursors, basophilia, and reduced leukocyte alkaline phosphatase activity, the latter serving as a diagnostic clue distinguishing CML from reactive leukocytosis. The cellular hyperplasia in bone marrow, particularly of granulocytic precursors, reflects the molecular pathogenesis, with cells retaining differentiation capacity but escaping normal proliferative constraints.

Answer the following true/false question.
Question: Colorectal cancer with synchronous liver metastases: does global management at the same centre improve results?
Options:
A. True
B. False

Please respond **only** with a single valid JSON object in the following format:
{"answer": "True"}  ← if the answer is true
{"answer": "False"} ← if the answer is false
Do not include any other text or comments. Output must be strictly JSON.